ArticleRheumatology (Oxford, England)2012
A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.
Article in Rheumatology (Oxford, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.Rheumatology international · 2016Pooled it
- Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy.Frontiers in immunology · 2025Review
- Identification of Disulfidptosis-Related Genes and Molecular Subgroups in Rheumatoid Arthritis for Diagnostic Model and Patient Stratification.Journal of inflammation research · 2025Article
- Imaging in inflammatory arthritis: progress towards precision medicine.Nature reviews. Rheumatology · 2023Review
- Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis.Arthritis research & therapy · 2022Article
- Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: A two-center study in Taiwan.Journal of the Chinese Medical Association : JCMA · 2022Article
- Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment.The patient · 2022Article
- Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.Arthritis research & therapy · 2021Article
- Design of an algorithm for the diagnostic approach of patients with joint pain.Clinical rheumatology · 2021Article
- Transforming clinical trials in rheumatology: towards patient-centric precision medicine.Nature reviews. Rheumatology · 2020Review
- Identification of Novel Native Autoantigens in Rheumatoid Arthritis.Biomedicines · 2020Article
- Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissueArthritis research & therapy · 2018Article
- Article
- Biologics registers in RA: methodological aspects, current role and future applications.Nature reviews. Rheumatology · 2017Review
- Differential activation of endocrine-immune networks by arthritis challenge: Insights from colony-specific responses.Scientific reports · 2017Article
- Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.Mediators of inflammation · 2017Article
- Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.Nature communications · 2016Article
- Article
- Neo-Epitopes--Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis.PloS one · 2016Article
- Management of juvenile idiopathic arthritis: hitting the target.Nature reviews. Rheumatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RA is a syndrome consisting of different pathogenetic subsets in which distinct molecular mechanisms may drive common final pathways. Recent work has provided proof of principle that biomarkers may be identified predictive of the response to targeted therapy. Based on new insights, an initial treatment algorithm is presented that may be used to guide treatment decisions in patients who have failed one TNF inhibitor. Key questions in this algorithm relate to the question whether the patient is a primary vs a secondary non-responder to TNF blockade and whether the patient is RF and/or anti-citrullinated peptide antibody positive. This preliminary algorithm may contribute to more cost-effective treatment of RA, and provides the basis for more extensive algorithms when additional data become available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.